Over the past 12 months, 10 insiders at VERACYTE, INC. filed 47 open-market SEC Form 4 transactions on VCYT: 0 purchases worth $0 and 47 sales worth $12.0M. Insiders have been net sellers over this period. The most recent filing was on Jun 18, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 18, 26 | Karin Eastham | SELL | 3.2K | $53.55 | $169K |
| Jun 4, 26 | Rebecca ChambersChief Financial Officer | SELL | 2.0K | $50.09 | $98K |
| May 20, 26 | Robert S Epstein | SELL | 10.0K | $44.01 | $440K |
| Mar 4, 26 | Rebecca ChambersChief Financial Officer | SELL | 13.9K | $36.33 | $506K |
| Mar 4, 26 | John LeiteChief Commercial Officer-CLIA | SELL | 5.3K | $35.19 | $185K |
| Mar 4, 26 | Annie McGuireSVP, General Counsel | SELL | 5.0K | $36.34 | $176K |
| Mar 4, 26 | Marc StapleyChief Executive Officer | SELL | 26.3K | $36.28 | $953K |
| Mar 2, 26 | Phillip G. FebboChief Scientific & Med Officer | SELL | 13.4K | $36.16 | $485K |
| Dec 16, 25 | Annie McGuireSVP, General Counsel | SELL | 10.6K | $43.68 | $459K |
| Dec 5, 25 | Karin EasthamDirector | SELL | 12.8K | $46.59 | $587K |
| Dec 4, 25 | Rebecca ChambersChief Financial Officer | SELL | 8.5K | $47.25 | $398K |
| Dec 4, 25 | John LeiteChief Commercial Officer-CLIA | SELL | 1.3K | $47.51 | $61K |
| Dec 4, 25 | Annie McGuireSVP, General Counsel | SELL | 720 | $47.51 | $34K |
| Dec 4, 25 | Marc StapleyChief Executive Officer | SELL | 4.4K | $47.35 | $209K |
| Nov 25, 25 | Evan/ Fa JonesDirector | SELL | 1.1K | $50.25 | $56K |
| Nov 25, 25 | John LeiteChief Commercial Officer-CLIA | SELL | 2.8K | $50.00 | $140K |
| Nov 20, 25 | Jens HolsteinDirector | SELL | 7.0K | $43.21 | $299K |
| Nov 10, 25 | Jonathan WygantVP, Chief Accounting Officer | SELL | 5.1K | $42.33 | $216K |
| Nov 7, 25 | Jonathan WygantVP, Chief Accounting Officer | SELL | 5.8K | $40.21 | $234K |
| Nov 5, 25 | Rebecca ChambersChief Financial Officer | SELL | 7.0K | $41.00 | $287K |
| Nov 5, 25 | Karin EasthamDirector | SELL | 9.7K | $40.02 | $387K |
| Nov 5, 25 | Evan/ Fa JonesDirector | SELL | 24.3K | $46.38 | $1.1M |
| Nov 5, 25 | Annie McGuireSVP, General Counsel | SELL | 6.5K | $40.00 | $259K |
| Oct 6, 25 | Phillip G. FebboChief Scientific & Med Officer | SELL | 8.3K | $36.02 | $301K |
| Oct 1, 25 | Robert S EpsteinDirector | SELL | 21.5K | $35.08 | $753K |
| Oct 1, 25 | John LeiteChief Commercial Officer-CLIA | SELL | 2.5K | $35.00 | $89K |
| Oct 1, 25 | Annie McGuireSVP, General Counsel | SELL | 2.2K | $35.00 | $76K |
| Sep 19, 25 | Annie McGuireSVP, General Counsel | SELL | 2.3K | $33.69 | $77K |
| Sep 4, 25 | Marc StapleyChief Executive Officer | SELL | 7.7K | $30.41 | $233K |
| Jun 13, 25 | Muna BhanjiDirector | SELL | 4.6K | $26.67 | $122K |
| Jun 13, 25 | Karin EasthamDirector | SELL | 4.6K | $26.66 | $122K |
| Jun 4, 25 | John LeiteChief Commercial Officer-CLIA | SELL | 2.8K | $27.20 | $76K |
| Mar 7, 25 | John LeiteChief Commercial Officer-CLIA | SELL | 5.0K | $31.96 | $160K |
| Mar 4, 25 | Phillip G. FebboChief Scientific & Med Officer | SELL | 4.5K | $33.95 | $147K |
| Mar 4, 25 | Annie McGuireSVP, General Counsel | SELL | 1.1K | $33.69 | $38K |
| Mar 4, 25 | Marc StapleyChief Executive Officer | SELL | 28.2K | $34.37 | $925K |
| Feb 27, 25 | John LeiteChief Commercial Officer-CLIA | SELL | 5.7K | $33.84 | $194K |
| Feb 3, 25 | Rebecca ChambersChief Financial Officer | SELL | 527 | $43.85 | $23K |
| Jan 2, 25 | Karin EasthamDirector | SELL | 5.3K | $40.50 | $213K |
| Dec 13, 24 | Marc StapleyChief Executive Officer | SELL | 5.2K | $44.14 | $225K |
| Dec 4, 24 | Phillip G. FebboChief Scientific & Med Officer | SELL | 3.9K | $44.09 | $173K |
| Dec 4, 24 | Annie McGuireSVP, General Counsel | SELL | 18.7K | $44.02 | $823K |
| Dec 3, 24 | Rebecca ChambersChief Financial Officer | SELL | 7.0K | $43.23 | $303K |
| Dec 3, 24 | John LeiteChief Commercial Officer-CLIA | SELL | 1.1K | $43.25 | $45K |
| Dec 3, 24 | Jonathan WygantVP, Chief Accounting Officer | SELL | 956 | $43.36 | $41K |
| Nov 27, 24 | Jonathan WygantVP, Chief Accounting Officer | SELL | 5.0K | $42.89 | $216K |
| Nov 19, 24 | Karin EasthamDirector | SELL | 10.1K | $38.76 | $392K |
| Nov 12, 24 | Rebecca ChambersChief Financial Officer | SELL | 15.3K | $38.34 | $586K |
| Nov 12, 24 | Robert S EpsteinDirector | SELL | 15.0K | $38.32 | $575K |
| Sep 19, 24 | Evan/ Fa JonesDirector | SELL | 5.2K | $35.23 | $182K |
Over the past 12 months, insiders at VERACYTE, INC. filed 0 open-market purchases worth $0 and 47 sales worth $12.0M on VCYT, which makes them net sellers over the period. The most recent Form 4 was filed on Jun 18, 26.
10 different insiders at VERACYTE, INC. filed open-market SEC Form 4 transactions on VCYT over the last 12 months.
InsiderTape plots every VCYT insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every VERACYTE, INC. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →